Pharmhouse Corp (PHSE) fair value: what the stock is really worth
We calculate from audited financials what Pharmhouse Corp is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jun 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Pharmhouse Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.
How to read this chart
60‑month range $0.0057 – $9.79 · fair‑value band $0.0425 – $0.0765 · the $0.0510 price screens below the $0.0595 fair value. Dashed = 300-day average. As of Jun 24, 2026.
Follow Pharmhouse in your weekly email
Every Wednesday you see whether Pharmhouse is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pride Holdings Group operates as a LGBTQ-focused entertainment, hospitality, and lifestyle company in the United States. It engages in the bar, pub, tavern, restaurant, hotels, nightclubs, and live adult entertainment industry businesses. The company was formerly known as Parliament House Enterprises, Inc.
Show more
Pride Holdings Group operates as a LGBTQ-focused entertainment, hospitality, and lifestyle company in the United States. It engages in the bar, pub, tavern, restaurant, hotels, nightclubs, and live adult entertainment industry businesses. The company was formerly known as Parliament House Enterprises, Inc. and changed its name to Pride Holdings Group in July 2025. Pride Holdings Group is based in Orlando, Florida.
Stock analysis
Pharmhouse Corp (PHSE) currently trades at $0.0510, while our model-based Fair Value estimate is $0.0595, implying the stock looks roughly 14.3% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0425 (bear) to $0.0765 (bull), the price of $0.0510 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Pharmhouse Corp reported revenue of $3.0M in FY2025 versus $14.6K in FY2015, a compound +70.5%/yr. Reported net income was −$9.4M in FY2025.
Key figures
Market cap $138M · EPS (TTM) $−0.0100 · Net margin −35.3% · Return on equity −56.7% · Return on assets (EBIT) −104% · Operating margin 19.6% · Revenue growth (YoY) +191% · Free cash flow −$2.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 77% below its 52-week high and 415% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −32% fair-value upside, at 17%, PHSE screens cheaper than that median.
Fair Value models
Bear $0.0425Fair Value $0.0595Bull $0.0765
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−30.9% (2018) → −301.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Lodging · 169 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside+17% · Top 25%
Profitability
Return on assets−6% · Bottom 25%
Net margin (TTM)−35% · Bottom 25%
Operating margin (TTM)20% · Above median
Growth and dividend
Revenue growth191% · Top 25%
Valuation Multiplesvs Lodging median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pharmhouse Corp Fair Value". https://www.fairvalue-calculator.com/stock/PHSE
Frequently asked questions
Is Pharmhouse Corp (PHSE) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0595 versus a price of $0.0510, about +17% upside (undervalued).
What is the fair value of PHSE?
Our model-based fair value for Pharmhouse Corp is $0.0595 (as of Jun 24, 2026), built from audited fundamentals. The current price: $0.0510.
What is the quality score of PHSE?
Pharmhouse Corp has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmhouse Corp (PHSE)?
Our model-based price target is the fair value of $0.0595 (as of Jun 24, 2026) from 1 valuation models. Cautious scenario $0.0425, optimistic scenario $0.0765. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmhouse Corp stock forecast for 2026?
Our models put fair value at $0.0595, about +17% upside versus a price of $0.0510 (undervalued). Cautious scenario $0.0425, optimistic scenario $0.0765. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Pharmhouse Corp (PHSE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmhouse Corp it is $0.0595 per share (as of Jun 24, 2026), against a price of $0.0510. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pharmhouse Corp stock overvalued or undervalued in 2026?
As of Jun 24, 2026, PHSE trades below its calculated fair value: price $0.0510, fair value $0.0595, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PHSE?
No. The price is what the market pays today ($0.0510); the fair value is what the company's own numbers justify ($0.0595). For Pharmhouse Corp the two are $0.0085 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmhouse Corp worth?
The market values Pharmhouse Corp at about $138M (market capitalisation, as of Jun 24, 2026). Per share that is $0.0510; our models calculate a fair value of $0.0595 per share.
What do the bullish and bearish scenarios say about PHSE?
Our models span a range for Pharmhouse Corp: cautious scenario $0.0425, base $0.0595, optimistic $0.0765 per share (as of Jun 24, 2026, price $0.0510). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pharmhouse Corp (PHSE)?
Balance-sheet figures for Pharmhouse Corp (as of Jun 24, 2026): return on equity −56.7%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is PHSE from its 52-week high?
Pharmhouse Corp trades at $0.0510, about 77% below its 52-week high of $0.2200 and 415% above the low of $0.0099 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0595 is for.
Which stocks are comparable to Pharmhouse Corp?
From the same area (Consumer Cyclical) we also value Marriott International, Inc, Hilton Worldwide Holdings, InterContinental Hotels Group, Hyatt Hotels Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmhouse Corp stock attractive at the current price?
The data as of Jun 24, 2026: price $0.0510, calculated fair value $0.0595 (+17%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PHSE calculated?
We run Pharmhouse Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0595, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Pharmhouse Corp currently trades 17 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmhouse Corp (PHSE)?
The closing price on Sep 23, 2026 was $0.0510. Our model-based fair value is $0.0595, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmhouse Corp right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Pharmhouse Corp
How large is the market capitalisation of Pharmhouse Corp (PHSE)?
The market capitalisation of Pharmhouse Corp is $138M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Pharmhouse Corp (PHSE)?
Earnings per share at Pharmhouse Corp are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pharmhouse Corp (PHSE)?
The net margin of Pharmhouse Corp is −35.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmhouse Corp (PHSE)?
The return on equity (ROE) of Pharmhouse Corp is −56.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmhouse Corp (PHSE)?
On an EBIT basis the return on assets of Pharmhouse Corp is −104% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmhouse Corp (PHSE)?
The operating margin of Pharmhouse Corp is 19.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmhouse Corp (PHSE)?
Revenue at Pharmhouse Corp is growing +191% versus a year earlier (3y avg +661%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pharmhouse Corp (PHSE) generate?
The free cash flow of Pharmhouse Corp is −$2.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmhouse Corp (PHSE) carry?
The net debt of Pharmhouse Corp is $4.7M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharmhouse Corp in the live analysis
One click puts Pharmhouse Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jun 24, 2026